Create a free Manufacturing.net account to continue

Judge Asked To Delay Amgen Takeover Of Micromet

Some Micromet shareholders are alleging that Micromet's board rushed it through and did not adequately explore whether it could get a better price.

DOVER, Del. (AP) -- Shareholders of Micromet Inc. are asking a Delaware judge to delay the company's acquisition by Amgen Inc., the world's largest biotech company.

Amgen has offered $11 per share for Micromet, a Maryland-based developer of cancer therapies, in a deal valued at more than $1 billion.

But some Micromet shareholders are challenging the acquisition, alleging that Micromet's board rushed it through and did not adequately explore whether it could get a competing offer at a better price.

Attorneys for Micromet and Amgen argued at a court hearing Monday that Micromet reached out to several other companies, but none expressed interest in making a bid.

The judge heard more than two hours of arguments but did not immediately issue a ruling. A tender offer for Micromet shareholders expires at midnight Thursday.

More in Supply Chain